Evaluation of Stability and Anti-cancer activity of Copper(II) Tolfenamic Acid with an emphasis on Pancreatic

Simple item page
dc.contributor.authorSankpal, Umesh
dc.contributor.authorPatel, Rafid
dc.contributor.authorChhabra, Jaya
dc.contributor.authorBrown, Deondra
dc.contributor.authorGurung, Raj
dc.contributor.authorHolder, Alvin
dc.contributor.authorRajasekhar, Maram
dc.contributor.authorBasha, Riyaz
dc.creatorHurtado, Myrna
dc.date.accessioned2019-08-22T20:06:28Z
dc.date.available2019-08-22T20:06:28Z
dc.date.issued2018-03-14
dc.date.submitted2018-02-05T09:36:57-08:00
dc.descriptionResearch Appreciation Day Award Winner - 2018 UNT Health Science Center, Interprofessionalism Poster Award - 1st Place
dc.description.abstractPurpose: Tolfenamic acid (TA) acts as an anti-cancer agent in several cancer models via down-regulating transcription factors Sp1 and Sp3, and an inhibitor of apoptotic protein, survivin. Copper (Cu) is an important element with multiple biological functions and has gained interest in medical applications. Recently, Cu-TA has been synthesized and tested for enhanced therapeutic activity. In this study, Cu-TA was investigated for its stability and anti-cancer activity using several cancer cell lines and mouse model for pancreatic cancer (PC). Method: Cu-TA was synthesized and characterized by UV visible spectroscopy and Fourier-transform infrared spectroscopy (FTIR). Anti-proliferative activity was evaluated against twelve cell lines representing six (breast, colon, glioblastoma, medulloblastoma, pancreatic and prostate) cancers using the CellTiter-Glo kit and compared with TA. Further studies were performed using PC cells. The expression of Sp1, Sp3 and survivin was determined by Western blot and qPCR. The stability of Cu-TA was determined using 8-12 month-old powder and six-month-old stock solution. Cardiomyocytes (H9C2) were used to test the cytotoxicity in non-malignant cells. Athymic mice were injected with PC cells and treated with vehicle (control) or 25 or 50 mg/kg of Cu-TA 3 times/week and the effect on tumor growth was monitored for 4 weeks Animals body weight changes were also observed to determine overt toxicity. Results: Cu-TA significantly more effective than TA against all tested cancer cells. The IC50 values of Cu-TA were 30 to 80% less when compared with TA. Comparison of the twelve-month-old powder and six-month-old stock solution using the Panc1 cells showed similar IC50values ( Conclusion: These in vitro and in vivo studies demonstrate that Cu-TA is more effective than TA and potentially useful as an effective anti-cancer agent.
dc.identifier.urihttps://hdl.handle.net/20.500.12503/27807
dc.language.isoen
dc.provenance.legacyDownloads0
dc.titleEvaluation of Stability and Anti-cancer activity of Copper(II) Tolfenamic Acid with an emphasis on Pancreatic
dc.typeposter
dc.type.materialtext

Files

Collections

Cancer